45P Immune-related adverse events: Spectrum and clinical features in the real world
Isabel Vieira(IPO Porto), João Antônio de Queiroz Oliveira(IPO Porto), Sofia Pinelas(IPO Porto), José Dinis(Instituto Português de Oncologia Francisco Gentil), C. Gaspar(IPO Porto)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
|Annals of Oncology|2017|90
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
|Cancer Chemotherapy and Pharmacology|2014|87